Evaluation of Tumor Markers in Endometrial Cancer Differentiation and Abnormal Uterine Bleeding

Endometrial cancer is recognized as the most frequently diagnosed malignancy of the female genital system. It is imperative to evaluate the discriminatory ability of specific tumor markers, namely, the Carcinoembryonic Antigen (CEA), Cancer Antigen ۱۵-۳ (CA ۱۵-۳), and Cancer Antigen ۱۲۵ (CA-۱۲۵). This evaluation becomes particularly significant in situations where patients exhibit symptoms of abnormal uterine bleeding (AUB). Our investigation evaluates of tumor markers in endometrial cancer differentiation and AUB. Methods & Materials: A comprehensive search was conducted utilizing reputable databases including Ovid, Elsevier, PubMed, and Google Scholar. The search encompassed literature published from the year ۲۰۱۴ to ۲۰۲۳ and was not restricted by language. A total of ۳۰ articles were initially identified, and after thorough summarization and analysis, ۲۰ articles were deemed relevant and selected for inclusion. Results: Upon meticulous examination of the data, it was discerned that the variation in serum concentrations of the CEA tumor marker in patients afflicted with endometrial cancer was of statistical significance. This observation was substantiated by a preponderance of the studies reviewed, which reported a statistically significant discrepancy in serum concentrations of the CEA tumor marker between patients diagnosed with endometrial cancer and those presenting with abnormal uterine bleeding. However, a comprehensive meta-analysis incorporating five distinct trials failed to establish a significant difference when comparing serum concentrations of the CA ۱۵-۳ and CA-۱۲۵ tumor markers in patients diagnosed with endometrial cancer and those exhibiting symptoms of abnormal uterine bleeding. Conclusion: Drawing upon the extant body of evidence, it can be postulated that the CEA marker may be judiciously utilized for the initial detection of endometrial cancer. Moreover, it could potentially be instrumental in the systematic monitoring of therapeutic progress among patients who have been diagnosed with this specific form of malignancy.

کلیدواژه ها:

tumor marker ، endometrial cancer ، uterine